譚啟龍,任 宜,楊章女,林君芬,葉 凌,李世波
?
舟山海島地區(qū)發(fā)熱伴血小板減少綜合征死亡病例特征和基因序列分析
譚啟龍1,任宜1,楊章女2,林君芬2,葉凌1,李世波3
1.浙江省岱山縣疾病預(yù)防控制中心,岱山316200;2.浙江省疾病預(yù)防控制中心,杭州310000;3.溫州醫(yī)科大學(xué)附屬舟山醫(yī)院,舟山316000
摘要:目的探討發(fā)熱伴血小板減少綜合征(SFTS)死亡病例的流行病學(xué)和臨床特征及病毒基因序列,為SFTS的防治提供科學(xué)依據(jù)。方法應(yīng)用病例-對(duì)照研究,對(duì)8例SFTS死亡病例(病例組)和24例存活病例(對(duì)照組)的臨床與流行病學(xué)信息進(jìn)行統(tǒng)計(jì)分析,利用MEGA5.1對(duì)毒株進(jìn)行系統(tǒng)發(fā)育分析。結(jié)果1)死亡病例組有田間勞作史的比例為50.00%,存活病例組為8.33%,二者有統(tǒng)計(jì)學(xué)差異(P=0.023),OR=11.00;死亡病例組家中養(yǎng)有動(dòng)物且動(dòng)物身上有蜱蟲發(fā)現(xiàn)比例為37.50%,存活病例組為4.17%,二者有統(tǒng)計(jì)學(xué)差異(P=0.039),OR=13.80。2)死亡病例組中有畏寒癥狀比例為25.00%,存活病例組為79.17%,(P=0.02),OR=0.08;死亡病例組中有腹瀉癥狀比例為37.50%,存活病例組為83.33%,(P=0.04),OR=0.12;死亡病例組中初診有體表淋巴結(jié)腫大比例為50.00%,存活病例組為12.50%,(P=0.04),OR=7.00。3)死亡病例組及存活病例組白細(xì)胞、血小板均低于正常水平,死亡病例組血小板均值高于存活病例組,且二者有統(tǒng)計(jì)學(xué)差異(P=0.02)。4)日本與這4株死亡病例所在的岱山島均為海島環(huán)境,其L、M核苷酸序列處于同一個(gè)進(jìn)化分支。然而基于S片段的進(jìn)化樹上江蘇的代表株也進(jìn)入到這個(gè)分支。結(jié)論有田間勞作、家中動(dòng)物身上有蜱蟲及初診體表淋巴結(jié)腫大的病例死亡風(fēng)險(xiǎn)較高,而有腹瀉及畏寒癥狀的病例死亡風(fēng)險(xiǎn)較低,醫(yī)務(wù)人員在診治過程中應(yīng)加以注意,另外布尼亞病毒在海島環(huán)境上可能有比較獨(dú)特的演化環(huán)境。
關(guān)鍵詞:發(fā)熱伴血小板減少綜合征;死亡病例;病例特征;基因序列
Supported by the Medical Science and Technology Plan projects in Zhejiang Province(No. 2014ZDA003, 2014RCA002), the Key Funding Scheme on Medical Platform of Zhejiang Province(No. 2012ZDA044), and the Zhoushan City Medical Health Youth Science and Technology Talents Specialized Research Plan(No. 2014Q01)
發(fā)熱伴血小板減少綜合征(severe fever with thrombocytopeniasyndrome,SFTS)經(jīng)證實(shí)是由新型布尼亞病毒感染導(dǎo)致的[1-2]一種自然疫源性疾病,近年來在我國不少地方都有病例報(bào)導(dǎo), 在我國的分布范圍進(jìn)一步擴(kuò)大[1],隨著診治水平及醫(yī)務(wù)人員防治意識(shí)的提高該病的報(bào)告率也有上升趨勢(shì)。根據(jù)國家衛(wèi)生和計(jì)劃生育委員會(huì)的調(diào)查數(shù)據(jù)顯示, SFTS分布在13個(gè)省份,病死率約為10%[3]。岱山縣是浙江省新型布尼亞病毒感染病例的高發(fā)縣[4],近幾年報(bào)告的病例數(shù)一直位居全省之首,病死率高,對(duì)人民群眾的健康帶來了極大的影響?,F(xiàn)通過對(duì)岱山縣2013-2014年死亡病例的臨床和流行病學(xué)數(shù)據(jù)分析,結(jié)果報(bào)告如下。
1材料與方法
1.1資料來源病例組(死亡病例)8例,對(duì)照組(一般病例)24例均來自國家疫情網(wǎng)絡(luò)報(bào)告系統(tǒng),且所有病例均為實(shí)驗(yàn)室確診病例,4株死亡病例病毒株由省、縣疾控中心分離并上報(bào)GenBank基因序列庫,在本文中為了便于識(shí)別,這4株死亡病例毒株基因組序列簡(jiǎn)稱為DS-1,DS-2,DS-3,DS-4。
1.2診斷標(biāo)準(zhǔn)根據(jù)流行病學(xué)史、臨床表現(xiàn)和實(shí)驗(yàn)室檢測(cè)結(jié)果進(jìn)行病例診斷,診斷標(biāo)準(zhǔn)參照《發(fā)熱伴血小板減少綜合征防治指南(2010版)》[5]。
1.3實(shí)驗(yàn)室檢測(cè)采集患者急性期(發(fā)病1周內(nèi))血液標(biāo)本:①抗凝血:用乙二胺四乙酸(EDTA)抗凝管或枸櫞酸鹽抗凝管采集5 mL,充分混勻。②血清:用無菌真空管采集患者急性期血液標(biāo)本5 mL,分離血清,冰排冷藏運(yùn)送縣CDC -70 ℃保存。檢測(cè)方法及試劑參照《發(fā)熱伴血小板減少綜合征防治指南(2010版)》[5]中的《實(shí)驗(yàn)室檢測(cè)方案》及參考文獻(xiàn)[6-8]。
1.4統(tǒng)計(jì)方法所有數(shù)據(jù)統(tǒng)一編碼后,采用Epi Data3.0軟件錄入數(shù)據(jù)庫。采用SPSS 18.0軟件對(duì)要素進(jìn)行統(tǒng)計(jì)分析,P<0.05有統(tǒng)計(jì)學(xué)意義。
1.5進(jìn)化樹分析利用MEGA5.1最大似然法進(jìn)行系統(tǒng)發(fā)育分析。
2結(jié)果
2.1流行特征除秀山鄉(xiāng)和衢山鎮(zhèn)無病例外,所有病例散發(fā)分布于岱山縣其他鄉(xiāng)鎮(zhèn),大多數(shù)病例居住于山區(qū)丘陵地帶,發(fā)病時(shí)間主要集中于 5-7月,以務(wù)農(nóng)和家務(wù)勞動(dòng)者居多。病例組與對(duì)照組在性別比例、年齡結(jié)構(gòu)、發(fā)病至就診時(shí)間、發(fā)病至確診時(shí)間等要素上均無統(tǒng)計(jì)學(xué)差異詳見(表1),所有病例均否認(rèn)有蜱蟲叮咬史,查體均未見皮膚破損且發(fā)病前無外出史,本地感染特征明顯。病例組中有田間勞作史的病例4例占比50.00%,對(duì)照組2例占比8.33%,差異具有統(tǒng)計(jì)學(xué)意義(P=0.03)OR=11.00(1.48,81.60);病例組家中養(yǎng)有動(dòng)物且動(dòng)物身上有蜱蟲發(fā)現(xiàn)的病例3例占比37.50%,對(duì)照組1例占比4.17%,差異有統(tǒng)計(jì)學(xué)意義(P=0.04)OR=13.80(1.18,161.71)。
2.2主要臨床表現(xiàn)除病例組中1例病例無發(fā)熱外,病例組和對(duì)照組其余病例首發(fā)癥狀均以發(fā)熱為主,體溫多在38 ℃以上,部分病例伴乏力、惡心、嘔吐等、頭痛、肌肉酸痛、腹瀉癥狀等。所有臨床表現(xiàn)中病例組與對(duì)照組除畏寒、腹瀉及體表淋巴結(jié)腫大有差異外,其余均無明顯差異,詳見表2。其中,病例組中有畏寒癥狀的病例2例占比25.00%,對(duì)照組19例占比79.17%,差異有統(tǒng)計(jì)學(xué)意義(P=0.02)OR=0.08(0.01,0.57);病例組中有腹瀉癥狀的病例3例占比37.50%,對(duì)照組20例占比83.33%,差異有統(tǒng)計(jì)學(xué)意義(P=0.04)OR=0.12(0.20,0.72);病例組中初診有體表淋巴結(jié)腫大的病例4例占比50.00%,對(duì)照組3例占比12.50%,差異有統(tǒng)計(jì)學(xué)意義(P=0.04)OR=7.00(1.11,44.06)。
表1 主要流行病學(xué)特征比較
表2 兩組臨床特點(diǎn)比較
2.3實(shí)驗(yàn)室檢測(cè)采集的患者急性期(發(fā)病1周內(nèi))血液標(biāo)本經(jīng)熒光RT-PCR法檢測(cè),病例組及對(duì)照組所有病例均為新型布尼亞病毒核酸陽性。初診血常規(guī)檢查顯示所有病例白細(xì)胞、血小板均低于正常水平,病例組血小板均值高于對(duì)照組,且二者有統(tǒng)計(jì)學(xué)差異(P=0.02),兩組的白細(xì)胞、中性粒細(xì)胞、淋巴細(xì)胞均值無明顯差異,詳見表2。
表3 兩組初診血液生化指標(biāo)比較
2.4核苷酸序列同源性和進(jìn)化樹分析4株死亡病例的新型布尼亞病毒毒株(基因組序列簡(jiǎn)稱為DS-1,DS-2,DS-3,DS-4,并在系統(tǒng)發(fā)育樹和核苷酸序列同源比對(duì)上加標(biāo)*號(hào))L、M、S三個(gè)基因片段的核苷酸序列同源性比對(duì)分別為96.5%~99.8%,98.9%~99.6%,97.9%~99%,4株病毒核苷酸序列呈高度同源性。與其余國內(nèi)外的布尼亞病毒代表株的L、M、S核苷酸序列同源性比對(duì)分別為83%~99.8%,86.3%~99.9%,87.2%~99.8%(S片段核苷酸序列同源性比對(duì)見表4)。利用MEGA5.1進(jìn)行的系統(tǒng)發(fā)育分析顯示,在基于L、M片段的進(jìn)化樹上,4株死亡病例的與來自日本的2株代表株以及浙江/01/2011株同處于一個(gè)相對(duì)獨(dú)立的進(jìn)化分支上(圖1,圖2)。中國其他省份,如河南、安徽、上海、湖北、山東、江蘇、遼寧等分離到的病毒處于另外一個(gè)進(jìn)化分支上。而在基于S片段的進(jìn)化樹上,江蘇,浙江以及日本的序列處于一個(gè)進(jìn)化分支上。
表4 S基因核苷酸序列同源性比對(duì)
圖1 L基因進(jìn)化樹
圖2 M基因進(jìn)化樹
3討論
近年來岱山縣SFTS的發(fā)病數(shù)位居浙江省前列,大多數(shù)病例分布于山區(qū)丘陵地帶,發(fā)病人群以務(wù)農(nóng)和家務(wù)勞動(dòng)者為主,這與該人群暴露機(jī)會(huì)較一般人群更大及自身免疫功能較低有關(guān)。研究中所有病例均否認(rèn)有蜱蟲叮咬史且查體均無皮膚破損,提示除蜱蟲外可能還有其他的傳播媒介。有田間勞作史及家中飼養(yǎng)動(dòng)物且動(dòng)物身上有蜱蟲發(fā)現(xiàn)這2個(gè)要素使病例的死亡風(fēng)險(xiǎn)升高。
畏寒及腹瀉使病例的死亡風(fēng)險(xiǎn)降低,這可能與腹瀉是病毒排出體外的一個(gè)重要途徑有關(guān),畏寒作用機(jī)制尚不明確;淋巴結(jié)腫大一般發(fā)生在STFS的發(fā)熱期,初診即有淋巴結(jié)腫大較無腫大者更接近于STFS的多器官功能障礙期[3,6],對(duì)病程而言其治療相對(duì)滯后,病例初診時(shí)體表淋巴結(jié)腫大是死亡風(fēng)險(xiǎn)升高的一個(gè)因素。白細(xì)胞和血小板計(jì)數(shù)降低是最早出現(xiàn)的實(shí)驗(yàn)室異常指標(biāo),降低比例均達(dá)到100%。WBC和PLT計(jì)數(shù)的降低,可作為該病早期診斷最靈敏的輔助指標(biāo)[9]。治療過程中發(fā)現(xiàn),初診血小板下降不明顯的病例病情進(jìn)展迅速,發(fā)展為重癥病例的幾率較大,這與結(jié)果中死亡組初診血小板均值高于對(duì)照組相吻合。
日本與這4株死亡病例所在的岱山島均為海島環(huán)境,其L、M核苷酸序列處于同一個(gè)進(jìn)化分支,可能揭示布尼亞病毒在海島環(huán)境上有比較獨(dú)特的演化環(huán)境。然而基于S片段的進(jìn)化樹上江蘇的代表株也進(jìn)入到這個(gè)分支。其在演化上的意義能有待進(jìn)一步研究。
STFS病死率較高可能與報(bào)告病例以老年人為主有關(guān),實(shí)際可能存在大量年輕的隱性感染者或癥狀輕微者,隨著診斷水平、醫(yī)務(wù)人員防治意識(shí)的提高及相關(guān)研究的進(jìn)一步深入,會(huì)有更多的輕癥病例被發(fā)現(xiàn),實(shí)際病死率或許會(huì)比現(xiàn)在低很多,雖然如此,但就STFS起病急,病程進(jìn)展迅速[5]的特點(diǎn)而言,做到早發(fā)現(xiàn)、早診斷、早治療,提高了病例的及時(shí)發(fā)現(xiàn)率和救治率,是顯著降低該病病死率的關(guān)鍵[10]。此類疾病早期癥狀與感冒、胃腸炎等類似,加之流行季節(jié)正是農(nóng)忙時(shí)節(jié),患者不能及早到醫(yī)療機(jī)構(gòu)就診 ,多自行服藥或在附近醫(yī)療條件有限的村鎮(zhèn)衛(wèi)生所進(jìn)行治療,使病程延誤,病情加重,甚至死亡[11-12],因此積極開展健康教育活動(dòng),采用多種有效宣傳方式提高群眾自我保護(hù)意識(shí),降低感染幾率也很重要。病例均為本地病例,導(dǎo)致樣本量較小,可能給研究結(jié)果帶來一定的偏倚,這也是本次研究較大的不足。
參考文獻(xiàn):
[1]Ding SJ, Lin Y, Zhang XM,et al. Research advances on epidemiology of severe fever with thrombocytopenia syndrome[J].Chin J Zoonoses, 2014, 30(5): 531-534.(in Chinese)
丁淑軍,林藝,張曉梅,等.發(fā)熱伴血小板減少綜合征流行病學(xué)研究進(jìn)展[J].中國人獸共患病學(xué)報(bào),2014,30(5):531-534.
[2]Yu XJ, Liang MF, Zhang SY, et al. Fever with thrombocytopenia assoeiatied with a novel bunyavirus in China[J].N Engl J Med, 2011, 364(16): 1523-1532. DOI: 10.1056/NEJ-Moal010095
[3]Gai ZT, Zhang Y, Liang MF, et al. Clinical progress and risk factors for death in severe fenet with thrombocytopenia syndrome patients[J].J Infect Dis, 2012, 206(7): 1095-1102. DOI: 10.1093/infdis/jis472
[4]Ye L,Ren Y,Wang ZF, et al. Surveillance and analysis 0f new Bunia virus infections in Zhoushan Island area during 2011-2012[J].Chin J Vector Biol Ctrl, 2013, 24(5): 429-431.(in Chinese)
葉凌,任宜,王忠發(fā),等.舟山海島地區(qū)2011-2012年新型布尼亞病毒感染監(jiān)測(cè)分析[J].中國媒介生物學(xué)及控制雜志,2013,24(5):429-431.
[5]Chinese Ministry of Health. Fever with thrombocytopenia syndrome prevention guide(2010)[S].Beijing: Chinese Ministry of Health. 2010.(in Chinese)
中華人民共和國衛(wèi)生部.發(fā)熱伴血小板減少綜合征防治指南(2010版)[S].北京:中華人民共和國衛(wèi)生部,2010.
[6]Sun LP, Tong QX, Jie SH. Research progress in severe fever with thrombocytopenia syndrome[J].Chin J Vector Biol Ctrl, 2014, 25(2): 87-89.(in Chinese)
孫立平,童巧霞,揭盛華.發(fā)熱伴血小板減少綜合征研究進(jìn)展[J].中國媒介生物學(xué)及控制雜志,2014,25(2):87-89.
[7]Zhang LP, Wang YCH, Zhao Y, et al. Research progress of epidemiology and detection method of severe fever with thrombocytopenia syndrome bunyavirus[J].Inspect Quarant Sci, 2014, 24(4): 67-72.(in Chinese)
張麗萍,王玉春,趙勇,等.新布尼亞病毒流行病學(xué)及檢測(cè)方法的研究進(jìn)展[J].檢驗(yàn)檢疫學(xué)刊,2014,24(4):67-72.
[8]Fu SW, Hu FJ, Wang ZF, et al. Establishment and application of indirect immunofluorescence assay(IFA) for detection of IgG antibody against new bunyavirus[J].Chin J Lab Med, 2015, 38(1): 1-4.(in Chinese)
傅松維,胡逢蛟,王忠發(fā),等.新布尼亞病毒IgG抗體間接免疫熒光檢測(cè)法的建立與應(yīng)用[J].中華檢驗(yàn)醫(yī)學(xué)雜志,2015,38(1):1-4.
[9]Hu JL, Bao CJ, Qi X, et al. Clinical and epidemiological characteristics on 20 cases of SFTSV infection[J].Chin J Zoonoses, 2012, 28(3): 302-305.(in Chinese)
胡建利,鮑昌俊,祁賢,等.20例人感染新布尼亞病毒的臨床和流行病學(xué)特征分析[J].中國人獸共患病學(xué)報(bào),2012,28(3):302-305.
[10]Ma Y, Yang ZD. Analyze the characteristics of main laboratory test results of 422 cases of fever with thrombocytopenia syndrome[J].Chin J Trauma Disability Med, 2014, 22(17): 142-144.(in Chinese)
馬 勇, 楊振東.422例發(fā)熱伴血小板減少綜合征主要實(shí)驗(yàn)室檢測(cè)結(jié)果的特征分析[J].中國傷殘醫(yī)學(xué),2014,22(17):142-144.
[11]You AG, Yang JH, Du YH, et al. Analysis of the epidemiological and pathogenic characteristics of severe fever with thrombocytopenia syndrome(SFTS)in Henan Province of China,2012-2013[J].J Pathog Biol, 2014, 9(6): 552-555.(in Chinese)
尤愛國 ,楊建華 ,杜燕華,等.2012-2013年河南省發(fā)熱伴血小板減少綜合征流行特征及病原學(xué)監(jiān)測(cè)分析[J].中國病原生物學(xué)雜志,2014,9(6):552-555.
[12]Qi SH, Pang W, Song LH. Monitoring and analysis of 422 case of fever with thrombocytopenia syndrome(SFTS)in Dalian City, 2011-2012[J]. Chin J Pest Ctrl, 2014, 30(6): 681-682.(in Chinese)
齊上,龐為,宋麗華.2011-2012年大連市發(fā)熱伴血小板減少綜合征病例監(jiān)測(cè)分析[J].醫(yī)學(xué)動(dòng)物防制,2014,30(6):681-682.
DOI:10.3969/j.issn.1002-2694.2016.01.015
通訊作者:任宜,Email:renyi1977@126.com
中圖分類號(hào):R558
文獻(xiàn)標(biāo)識(shí)碼:A
文章編號(hào):1002-2694(2016)01-0070-06
Corresponding author:Ren Yi, Email:renyi1977@126.com
收稿日期:2015-05-26;修回日期:2015-11-05
Epidemiology, clinical characteristics and gene sequence of fatal cases of severe fever with thrombocytopenia syndrome in Zhoushan island, China
TAN Qi-long1,REN Yi1,YANG Zhang-nyu2,LING Jun-fen2,YE Lin1,LI Shi-bo3
(1.DaishanCenterforDiseaseControlandPrevention,Zhoushan316200,China;2.ZhejiangCenterforDiseaseControlandPrevention,Hangzhou310000,China;3.DepartmentofInfectiousDisease,ZhoushanHospital,WenzhouMedicalUniversity,Zhoushan316000,China)
Abstract:In this paper, we explored the epidemiology, clinical characteristics and gene sequence of virus on fatal cases of severe fever with thrombocytopenia syndrome(SFTS), providing the basis for the scientific prevention and treatment of SFTS. The clinical and epidemiological information of 8 fatal cases(case group) and 24 non-fatal cases(control group) of SFTS were analyzed by statistics using case-control study and phylogeny was analyzed using MEGA5.1. Results showed that the proportions of field work history in case group and control group were 50% and 8.33%, respectively. There was statistical significance for field work history between two groups(P=0.023), OR=11.00. The proportions of raising animals and found ticks on animals in case group and control group were 37.5% and 4.17%, respectively. There was statistical significance for proportions of raising animals and found ticks on animals between two groups(P=0.039), OR=13.80. The proportions of clinical manifestation of chills in case group and control group were 25% and 79.17%, diarrhea were 37.50% and 83.33%, and lymphadenopathy were 50% and 12.5%, respectively. There were statistical significances for the clinical manifestations of chills, diarrhea and lymphadenopathy between two groups,(P=0.02, OR=0.08),(P=0.04, OR=0.12) and(P=0.04, OR=7.00), respectively. The mean of platelet counts in case group was higher than that in control group with statistical significance(P=0.02). The living environment of 4 fatal case patients which occurred in Daishan Island was island environmental, which was similar to Japan. Their L and M nucleotide sequence were in the same evolutionary branch. But, due to the represent strain of Jiangsu was also in the same evolutionary branch with Daishan Island and Japan on S fragment evolutionary tree. The patients who are raising animals and found ticks on animals, have field work history and lymphadenopathy are at higher risk of death. But the patitents with clinical symptoms of diarrhea and chills are at lower risk of death. The medical personnel should pay more attention in the process of diagnosis and treatment. In addition, the island environmental may provide unique environment of evolution for new bunyavirus.
Keywords:severe fever with thrombocytopeniasyndrome(SFTS); fatal cases; clinicopathological features; gene sequence
浙江省醫(yī)藥衛(wèi)生科技計(jì)劃(2014ZDA003,2014RCA002)、浙江省醫(yī)藥衛(wèi)生平臺(tái)重點(diǎn)資助計(jì)劃(2012ZDA044)、舟山市醫(yī)藥衛(wèi)生青年科技人才專項(xiàng)科研計(jì)劃(2014Q01)聯(lián)合資助